In this presentation from Lymphoma & Myeloma 2016, Dr. Steven Coutre provides an update on approved tyrosine-kinase inhibitors (TKIs) and their use in clinical practice for the treatment of chronic lymphocytic leukemia (CLL).
Click to Earn CME Credit: http://bit.ly/2lDPthL
© 2016 Imedex, LLC.